Browse the evidence

Tirzepatide significantly increases the risk of gastrointestinal adverse events, including nausea, vomiting, and diarrhea, compared to placebo.

Be prepared for potential stomach issues like nausea, vomiting, and diarrhea when starting tirzepatide. These side effects are common and significantly more likely than with a placebo. Starting at a low dose and increasing slowly can help your body adjust. If side effects are severe, talk to your doctor about adjusting your dose or stopping the medication.

Time-restricted eating (TRE) significantly increases low-density lipoprotein (LDL) cholesterol levels in adults with overweight and obesity, although it does not significantly alter total cholesterol, HDL, or triglycerides.

While TRE helps reduce body fat, be aware that it may slightly increase your LDL ('bad') cholesterol. This increase was statistically significant but the authors note it does not pose a significant safety concern for most. If you have existing heart conditions or high cholesterol, monitor your levels and consult a doctor.

A 12-month 4:3 intermittent fasting protocol does not produce different changes in fasting appetite-related hormones (leptin, ghrelin, PYY, BDNF, adiponectin) compared to daily caloric restriction when energy deficits are matched.

Don't expect intermittent fasting to magically fix your hunger hormones differently than daily calorie counting. The benefit of 4:3 IMF comes from how it changes your eating behaviors and psychological relationship with food, not from a unique hormonal advantage.

A modest reduced-calorie diet does not significantly alter plasma levels of Brain-Derived Neurotrophic Factor (BDNF) or glycemic factors (glucose, insulin, HOMA-IR) in overweight/obese adults with cardiovascular risk factors over a two-month period.

While cutting calories helps your cholesterol and blood pressure, it might not immediately change your blood sugar levels or brain-derived neurotrophic factor (BDNF) levels in just two months. This doesn't mean the diet isn't working; it means these specific markers may take longer to respond or may not respond in everyone, especially if you are already on medication. Focus on the improvements you can see, like weight and lipid profiles.

Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.

High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.

The AGEs/RAGE axis contributes to pancreatic beta cell toxicity and apoptosis via oxidative stress and islet amyloid polypeptide (IAPP) aggregation.

Preserving beta cell function is crucial; strategies that reduce AGEs and oxidative stress may help protect pancreatic beta cells.

MBS significantly reduces the risk of developing obesity-associated cancers and cancer-related mortality.

Undergoing MBS not only helps with weight but also significantly lowers your long-term risk of developing various cancers and dying from cancer compared to remaining obese.

Excessive ROS generation and depletion of antioxidants cause oxidative stress, which promotes endothelial dysfunction, leading to insulin resistance, hypertension, and dyslipidemia, thereby contributing to metabolic syndrome.

Focus on reducing the sources of oxidative stress: manage body weight, improve diet quality (e.g., Mediterranean diet, time-restricted eating), and increase physical activity. These interventions address the root causes (obesity, hyperglycemia) that drive excessive ROS production and subsequent metabolic dysfunction.

SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and heart disease or heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs not only help control blood sugar but have been proven to significantly reduce the risk of heart attacks, strokes, and hospitalizations for heart failure, regardless of your current blood sugar levels.

DNA methylation levels in specific genes (e.g., PGC-1α, FTO, TCF7L2) are altered in patients with Type 2 Diabetes and obesity, serving as potential biomarkers for diagnosis and treatment response.

Blood tests measuring DNA methylation patterns (epigenetic biomarkers) may soon help predict who is at risk for diabetes or who will respond to specific drugs like metformin, allowing for more personalized prevention and treatment strategies.

Targeting de novo lipogenesis (DNL) via ACC inhibitors (e.g., GS-0976, MK-4074) significantly reduces hepatic steatosis and DNL in patients with NASH.

ACC inhibitors like GS-0976 are being tested to directly reduce liver fat production. In trials, 20mg daily for 12 weeks reduced liver fat by 29%, significantly better than placebo. This is a pharmacological option for those who may not achieve sufficient weight loss through lifestyle alone.

Obese visceral fat inflammation is an initially protective adaptive response to restore metabolic homeostasis, but becomes detrimental when structural damage and senescence trigger chronic immune infiltration.

Understand that inflammation in fat tissue is not just 'damage' but a complex signal. In the early stages of weight gain, it helps your body adapt to storing more energy. However, if this stress continues, the system breaks down, leading to structural damage and chronic disease. The goal is not to blindly suppress inflammation but to address the root cause: excess nutrient influx and adipocyte overload.

Adipocyte hypertrophy and subsequent endoplasmic reticulum stress trigger a pro-inflammatory response (metaflammation) that initially preserves metabolic control by promoting lipolysis and tissue remodeling.

As fat cells grow larger, they become stressed and send out signals to break down fat and remodel tissue. This is a natural attempt to manage excess energy. If this system works, you may remain metabolically healthy despite being overweight.

Chronic structural damage in visceral fat, characterized by adipocyte death and senescence, shifts inflammation from protective to detrimental by recruiting circulating immune cells and causing fibrosis.

When fat cells die or become senescent, they release signals that attract immune cells, leading to chronic inflammation and scarring (fibrosis). This is the stage where metabolic health typically declines.

Genetic factors, particularly polymorphisms affecting neurotransmitter systems (dopamine, serotonin) and metabolic traits (BMI, insulin resistance), significantly increase the risk of developing eating disorders, with distinct genetic architectures for anorexia nervosa versus binge-type disorders.

If you have a family history of eating disorders, you may have a biological predisposition. This is not your fault, but it is a risk factor you can manage. Focus on early identification of symptoms and seek professional support if you notice changes in eating habits or body image, as genetic risk can be mitigated by environmental factors.

Childhood trauma, abuse, and neglect are strongly linked to the development of eating disorders, particularly Bulimia Nervosa and Binge Eating Disorder, through interactions with genetic susceptibility.

If you have experienced childhood trauma, you may be at higher risk for eating disorders. This risk is not inevitable, but it is significant. Trauma-informed therapy and support can help address the underlying emotional pain that may manifest as disordered eating.

Chronic hyperglycemia induces oxidative stress via multiple metabolic pathways (polyol, AGE, PKC, hexosamine), which directly causes insulin resistance and beta-cell dysfunction, leading to Type 2 Diabetes.

Managing blood sugar levels is critical not just for immediate comfort, but to prevent the cellular oxidative stress that drives long-term complications like nerve and kidney damage. Focus on dietary strategies that minimize glucose spikes to reduce the metabolic burden on your cells.

Aging adipose tissue undergoes early structural and functional decline, characterized by visceral fat redistribution, loss of brown/beige fat, and accumulation of senescent cells, which drives systemic metabolic dysfunction and accelerates aging.

Your fat cells are not just storage; they are active organs that signal your body's health status. As you age, these signals can become harmful, leading to inflammation and metabolic issues. Maintaining healthy adipose tissue through balanced nutrition and activity is crucial for slowing down age-related decline.

Intermittent administration of the senolytic drug combination dasatinib and quercetin (D&Q) reduces senescence and inflammation in adipose tissue, leading to improved systemic metabolic function (fasting glucose, glucose tolerance, and lipid profiles) in old age.

For older adults, intermittent treatment with dasatinib and quercetin may improve metabolic health by clearing senescent cells from fat tissue, reducing inflammation, and improving glucose tolerance. This suggests that targeting cellular aging could be a viable strategy for managing age-related metabolic decline.

Chronic systemic inflammation drives skeletal muscle atrophy by directly activating pro-catabolic signaling pathways (NF-κB, JAK/STAT, p38MAPK) that increase protein degradation via UPS/ALP and inhibit protein synthesis via IGF-1/Akt/mTOR suppression.

If you are experiencing muscle loss alongside a chronic inflammatory condition (like autoimmune disease, diabetes, or chronic infection), standard resistance training and high protein intake may be insufficient on their own. Medical management of the underlying inflammation is critical to stop the biological signals that actively break down muscle tissue.

Inflammation indirectly causes muscle atrophy by dysregulating the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to excessive glucocorticoid release, which further inhibits muscle protein synthesis and promotes proteolysis.

Managing stress and underlying inflammation is crucial because chronic stress and inflammation can trigger hormonal responses (cortisol) that actively break down muscle. Medical interventions that stabilize the HPA axis or reduce inflammatory cytokines may help preserve muscle mass.

Myostatin (MSTN) levels are increased by inflammatory factors (TNF-α, IL-6) and act as a negative regulator of muscle mass by activating the Smad2/3 pathway, which upregulates E3 ubiquitin ligases (MuRF1, Atrogin-1) and inhibits satellite cell recruitment.

High levels of inflammatory cytokines can increase Myostatin, a protein that naturally limits muscle growth. In chronic disease, this system is overactive, contributing to muscle loss. Therapies targeting Myostatin or its receptors are being investigated to counteract this loss.

GLP-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and inhibiting the NF-κB pathway, independent of glycemic control.

GLP-1 medications like semaglutide and liraglutide do more than just lower blood sugar; they actively reduce systemic inflammation by blocking key inflammatory pathways (NF-κB) and lowering pro-inflammatory cytokines. This benefit exists regardless of whether your blood sugar improves, suggesting these drugs may help with inflammatory conditions beyond diabetes.

Obesity induces low-grade chronic inflammation in white adipose tissue (WAT) via adipocyte death (apoptosis/necroptosis), which recruits pro-inflammatory macrophages (forming crown-like structures) and triggers systemic insulin resistance and metabolic syndrome.

Obesity is not just about storing fat; it is an active inflammatory state. Excess fat, especially visceral fat, leads to adipocyte death, which triggers an immune response (inflammation) that blocks insulin signaling. To improve metabolic health, strategies must address this underlying inflammation, not just caloric intake, by supporting adipose tissue health and reducing cytokine-driven resistance.